Authors: Gunduz, Mehmet; Beder, Levent Bekir¹; Gunduz, Esra; Nagatsuka, Hitoshi²; Fukushima, Kunihiro³; Pehlivan, Davut⁴; Cetin, Eren⁵; Yamanaka, Noboru¹; Nishizaki, Kazunori³; Shimizu, Kenji⁶; Nagai, Noriyuki²

Source: Cancer Science, Volume 99, Number 3, March 2008 , pp. 531-538(8)

Publisher: Wiley-Blackwell

Abstract:

Although many clinical and pathological prognostic factors such as tumor stage and lymph-node involvement have been described, to date no reliable or clinically applicable marker or tumor aggressiveness has been identified for head and neck cancer. In an attempt to identify such a molecular prognostic marker, we analyzed the mRNA expression status of ING3 by quantitative reverse transcription-polymerase chain reaction. We also examined p53 mutation status and investigated its relationship with ING3, as well its clinicopathological characteristics. About half of the 71 tumor samples demonstrated downregulation of ING3 compared to their matched normal counterparts. Although most clinicopathological variables were not significantly related to ING3 downregulation or p53 mutation status, a significant relationship was detected in terms of overall survival between the cases with low and normal to high ING3 expression. At 5 years follow up, approximately 60% of the patients with normal to high ING3 expression survived, whereas this was 35% in the patients with low ING3 expression. Multivariate analysis also showed downregulation of ING3 as an independent prognostic factor for poor overall survival. These results reveal that ING3 would function as a potential tumor suppressor molecule and that low levels of ING3 may indicate an aggressive nature of head and neck cancer. (Cancer Sci 2008; 99: 531-538)

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1349-7006.2007.00708.x

Affiliations: 1: Department of Otolaryngology, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8509, Japan; 2: Oral Pathology and Medicine, 3: Otolaryngology, and 4: Department of Medical Genetics, Istanbul University Istanbul Medical Faculty, Turkey; 5: Division of Gene Therapy Science, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita-City, Osaka 565-0871, Japan 6: Molecular Genetics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikatacho 2-5-1, Okayama;

Publication date: 2008-03-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology
• By this author: Gunduz, Mehmet ;  Beder, Levent Bekir ;  Gunduz, Esra ;  Nagatsuka, Hitoshi ;  Fukushima, Kunihiro ;  Pehlivan, Davut ;  Cetin, Eren ;  Yamanaka, Noboru ;  Nishizaki, Kazunori ;  Shimizu, Kenji ;  Nagai, Noriyuki

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers